Camurus AB (CAMX) - Total Assets
Based on the latest financial reports, Camurus AB (CAMX) holds total assets worth Skr4.74 Billion SEK (≈ $510.10 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Camurus AB (CAMX) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Camurus AB - Total Assets Trend (2011–2025)
This chart illustrates how Camurus AB's total assets have evolved over time, based on quarterly financial data. Check earnings quality score of Camurus AB to evaluate the quality of earnings relative to operating cash generation.
Camurus AB - Asset Composition Analysis
Current Asset Composition (December 2025)
Camurus AB's total assets of Skr4.74 Billion consist of 93.6% current assets and 6.4% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr3.73 Billion | 78.6% |
| Accounts Receivable | Skr600.38 Million | 12.7% |
| Inventory | Skr111.62 Million | 2.4% |
| Property, Plant & Equipment | Skr278.83 Million | 5.9% |
| Intangible Assets | Skr21.58 Million | 0.5% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2011–2025)
This chart illustrates how Camurus AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Camurus AB.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Camurus AB's current assets represent 93.6% of total assets in 2025, an increase from 83.9% in 2011.
- Cash Position: Cash and equivalents constituted 78.6% of total assets in 2025, up from 0.0% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 4.0% in 2011.
- Asset Diversification: The largest asset category is cash and equivalents at 78.6% of total assets.
Camurus AB Competitors by Total Assets
Key competitors of Camurus AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $763.95 Million |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
|
China | CN¥4.48 Billion |
|
Novavax Inc
NASDAQ:NVAX
|
USA | $1.04 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Camurus AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 12.09 | 8.09 | 3.56 |
| Quick Ratio | 11.78 | 7.77 | 2.96 |
| Cash Ratio | 10.15 | 6.50 | 0.00 |
| Working Capital | Skr4.07 Billion | Skr3.11 Billion | Skr467.49 Million |
Camurus AB - Advanced Valuation Insights
This section examines the relationship between Camurus AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.77 |
| Latest Market Cap to Assets Ratio | 0.70 |
| Asset Growth Rate (YoY) | 26.2% |
| Total Assets | Skr4.74 Billion |
| Market Capitalization | $3.33 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Camurus AB's assets below their book value (0.70x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Camurus AB's assets grew by 26.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Camurus AB (2011–2025)
The table below shows the annual total assets of Camurus AB from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr4.74 Billion ≈ $510.10 Million |
+26.16% |
| 2024-12-31 | Skr3.76 Billion ≈ $404.31 Million |
+96.93% |
| 2023-12-31 | Skr1.91 Billion ≈ $205.31 Million |
+46.14% |
| 2022-12-31 | Skr1.31 Billion ≈ $140.49 Million |
+20.67% |
| 2021-12-31 | Skr1.08 Billion ≈ $116.43 Million |
+3.62% |
| 2020-12-31 | Skr1.04 Billion ≈ $112.36 Million |
+35.24% |
| 2019-12-31 | Skr772.05 Million ≈ $83.08 Million |
+111.68% |
| 2018-12-31 | Skr364.72 Million ≈ $39.25 Million |
-23.37% |
| 2017-12-31 | Skr475.93 Million ≈ $51.22 Million |
-25.61% |
| 2016-12-31 | Skr639.78 Million ≈ $68.85 Million |
-21.63% |
| 2015-12-31 | Skr816.35 Million ≈ $87.85 Million |
+293.10% |
| 2014-12-31 | Skr207.67 Million ≈ $22.35 Million |
+85.99% |
| 2013-12-31 | Skr111.66 Million ≈ $12.02 Million |
+94.51% |
| 2012-12-31 | Skr57.41 Million ≈ $6.18 Million |
-34.65% |
| 2011-12-31 | Skr87.85 Million ≈ $9.45 Million |
-- |
About Camurus AB
Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029… Read more